Implementing the AI Act in the Portuguese Health Sector: Implications, Challenges and the CPIA-OM Perspective
DOI:
https://doi.org/10.20344/amp.24588Keywords:
Artificial Intelligence/ethics, Artificial Intelligence/legislation & jurisprudence, Device Approval, Electronic Health Record, Europe, European Union, Medical Device Legislation, PortugalAbstract
The rapid expansion of artificial intelligence (AI) in the health sector has intensified the need for a robust regulatory framework capable of safeguarding patient safety, professional accountability, and public trust. We aimed to analyse the European Union Artificial Intelligence Act [AI Act, Regulation (EU) 2024/1689] and its implications for the healthcare sector in Portugal, presenting the institutional position of the Artificial Intelligence Committee of the Portuguese Medical Association (CPIA-OM). We conducted a narrative review based on official European legislation [AI Act, General Data Protection Regulation (GDPR), Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR)], institutional documents [including the 2025 White Paper on AI in Healthcare in Portugal, published by the Shared Services of the Ministry of Health (SPMS)], and peer-reviewed literature on artificial intelligence in medicine, ethics, and regulatory science. The AI Act introduces a risk-based classification of AI systems, ranging from prohibited “unacceptable risk” applications to minimal risk uses. Most medical AI applications, including diagnostic support, clinical monitoring, and therapeutic decision-making, are classified as “high risk” and are subject to stringent requirements regarding conformity assessment, technical documentation, human oversight, and data governance. The regulation interacts with existing frameworks such as the GDPR and MDR/IVDR, creating complex compliance obligations. Specific challenges include algorithmic bias, liability attribution, and the preservation of the physician-patient relationship. In Portugal, recent institutional initiatives within the National Health Service — including pilot projects in triage, frailty assessment, antibiotic stewardship, and medical imaging — illustrate opportunities for responsible AI integration, while academic reports highlight persistent concerns around transparency, trust, and professional substitution. The AI Act represents a landmark in European health regulation, balancing innovation with fundamental rights protection. For Portugal, its implementation requires coordinated action between the government, regulators, healthcare providers, and professional bodies. The CPIA-OM emphasises the need for continuous medical education in AI, the establishment of clinical oversight protocols, and the creation of observatories to monitor implementation and ensure ethical, safe, and patient-centred adoption.
Downloads
References
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44-56.
Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health care: the hope, the hype, the promise, the peril. Nat Med. 2022;28:31-8.
Vokinger KN, Feuerriegel S, Kesselheim AS. Mitigating bias in machine learning for medicine. Lancet Digit Health. 2021;3:e375-85.
Veale M, Zuiderveen Borgesius F. Demystifying the European Union Artificial Intelligence Act. Comput Law Rev Int. 2021;22:97-112.
Heaven WD. The EU’s AI Act is here. MIT Technol Rev. 2024. [consultado 2025 nov 18]. Disponível em: https://www.technologyreview.com/2024/03/13/1089013/eu-ai-act-approved/.
Price WN, Gerke S, Cohen IG. Potential liability for physicians using artificial intelligence. JAMA. 2019;322:1765-6.
Miller DD, Brown EW. Artificial intelligence in medical practice: the question to the answer? Am J Med. 2018;131:129-33.
World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: WHO; 2021.
Organisation for Economic Co-operation and Development. Recommendation of the Council on Artificial Intelligence. OECD/LEGAL/0449. Paris: OECD; 2019.
Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 laying down harmonised rules on artificial intelligence (AI Act). Off J Eur Union. 2024.
Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366:447-53.
Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation — GDPR). Off J Eur Union. 2016.
Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (Medical Device Regulation — MDR). Off J Eur Union. 2017.
Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices (In Vitro Diagnostic Medical Devices Regulation — IVDR). Off J Eur Union. 2017.
Serviços Partilhados do Ministério da Saúde. White paper: inteligência artificial na saúde em Portugal. Lisboa: SPMS; 2025.
Grupo CUF. Rastreio de cancro da mama com inteligência artificial — software Transpara. [consultado 2025 abr 15]. Disponível em: https://www.cuf.pt/tecnologia-transparar.
DigestAID. Digestive artificial intelligence development. [consultado 2025 abr 16]. Disponível em: https://digestaid.health.
Coiera E, Hron C, Laranjo L. The AI scribe: automating clinical documentation. NPJ Digit Med. 2024;7:15.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Médica Portuguesa

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.



